Myelography using iohexol (Omnipaque)

Area of Science:

• Radiology
• Neurology
• Pharmacology

Background:

• Myelography is a diagnostic imaging procedure used to visualize the spinal canal.
• Non-ionic contrast agents are preferred for myelography due to their lower osmolality and reduced adverse effects.
• Iohexol is a widely used non-ionic, low-osmolar iodinated contrast medium.

Purpose of the Study:

• To evaluate the safety and tolerability of iohexol in patients undergoing myelography.
• To assess the incidence of adverse reactions following iohexol administration for myelography.
• To monitor neurological status and electroencephalogram (EEG) changes post-myelography.

Main Methods:

• Myelography was performed in 30 patients using iohexol (Omnipaque) at concentrations of 240 mg I/ml (C1-C2 injections) or 300 mg I/ml (lumbar injections).
• Doses ranged from 3 to 10 ml.
• Patients were monitored for 48 hours for adverse reactions, with neurological examinations repeated at 24 hours and EEG recordings taken between 3-24 hours post-procedure.

Main Results:

• Adverse reactions were reported in 4 out of 30 patients (13.3%).
• Minor EEG changes were observed in 1 patient (3.3%).
• Slight alterations in neurological status were noted in 2 patients (6.7%).

Conclusions:

• Iohexol appears to be a safe and well-tolerated contrast agent for myelography.
• The incidence of adverse reactions and neurological changes associated with iohexol myelography is low.
• Further studies may be warranted to confirm these findings in larger patient cohorts.